UY32754A - NUEVOS DERIVADOS DE 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA - Google Patents

NUEVOS DERIVADOS DE 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA

Info

Publication number
UY32754A
UY32754A UY0001032754A UY32754A UY32754A UY 32754 A UY32754 A UY 32754A UY 0001032754 A UY0001032754 A UY 0001032754A UY 32754 A UY32754 A UY 32754A UY 32754 A UY32754 A UY 32754A
Authority
UY
Uruguay
Prior art keywords
pirimido
tetrahidro
pirimidin
ona
pharmaceutical
Prior art date
Application number
UY0001032754A
Other languages
English (en)
Inventor
Baptiste Ronan
Annie Clauss
Gilbert Marciniak
Bertrand Vivet
Eric Bacque
Maurice Brollo
El Ahmad Youssef
Filoche-Rommr Bruno
Frank Hally
Karlsson Karl Andress
Laurent Schio
Fabrice Viviani
Andre Zimmermann
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0903237A external-priority patent/FR2947551B1/fr
Priority claimed from FR0957069A external-priority patent/FR2951174B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY32754A publication Critical patent/UY32754A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a derivados de 1, 2, 3, 4-tetrahidro -pirimido{1,2a}pirimidin-6-ona de la fórmula (I), en la que los radicales y sustituyentes son tales como se especifican en la Memoria descriptiva y en las especificaciones, estando estos productos en todas las formas isómeras y las sales, como medicamentos.
UY0001032754A 2009-07-02 2010-07-02 NUEVOS DERIVADOS DE 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA UY32754A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0903237A FR2947551B1 (fr) 2009-07-02 2009-07-02 Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
US24109809P 2009-09-10 2009-09-10
FR0957069A FR2951174B1 (fr) 2009-10-09 2009-10-09 Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Publications (1)

Publication Number Publication Date
UY32754A true UY32754A (es) 2011-01-31

Family

ID=43234240

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032754A UY32754A (es) 2009-07-02 2010-07-02 NUEVOS DERIVADOS DE 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA

Country Status (24)

Country Link
US (1) US8846670B2 (es)
EP (1) EP2448940B1 (es)
JP (1) JP5655070B2 (es)
KR (1) KR20120103553A (es)
CN (1) CN102482286B (es)
AR (1) AR077363A1 (es)
AU (1) AU2010267815B2 (es)
BR (1) BRPI1015943A8 (es)
CA (1) CA2766909C (es)
DK (1) DK2448940T3 (es)
ES (1) ES2487623T3 (es)
HK (1) HK1169388A1 (es)
HR (1) HRP20140786T1 (es)
IL (1) IL217293A (es)
MX (1) MX2012000103A (es)
MY (1) MY155661A (es)
PL (1) PL2448940T3 (es)
PT (1) PT2448940E (es)
RU (1) RU2561130C2 (es)
SG (2) SG10201403149YA (es)
SI (1) SI2448940T1 (es)
TW (1) TWI455940B (es)
UY (1) UY32754A (es)
WO (1) WO2011001113A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2655375B1 (fr) * 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
FR2969613B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
EP3266455B1 (en) 2015-03-06 2020-12-30 Korea Advanced Institute of Science and Technology Composition for prevention or treatment of intractable epilepsy comprising mtor inhibitor
US11077113B2 (en) 2016-02-19 2021-08-03 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
PL3416957T3 (pl) 2016-02-19 2021-02-08 Sprint Bioscience Ab Związki 6-heterocyklilo-4-morfolino-4-ylopirydyn-2-onu przydatne w leczeniu raka i cukrzycy
WO2021222295A1 (en) * 2020-04-27 2021-11-04 Aruna Bio, Inc. Binding agents and uses thereof for central nervous system delivery

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2703712A1 (de) 1977-01-29 1978-08-03 Bayer Ag Substituierte pyrimidinon eckige klammer auf (di)-thio eckige klammer zu -phosphor-(phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide, akarizide und nematizide
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
NZ520300A (en) 2000-01-24 2004-05-28 Kinacia Pty Ltd Morpholino-substituted pyridopyrimidine, quinolone and benzopyranone derivatives that inhibit the enzyme phosphoinositide (PI) 3-kinase
EP1315731B1 (en) * 2000-09-01 2004-06-16 Sanofi-Synthelabo 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
DK1430057T3 (da) * 2001-09-21 2006-01-16 Sanofi Aventis Substituerede 2-pyridinyl-6,7,8, 9-tetrahydropyrimido [1,2-a] pyrimidin-4-on- og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivater
EP1340761A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
AU2003221500B9 (en) * 2002-02-28 2008-11-20 Mitsubishi Pharma Corporation Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
JP4646626B2 (ja) 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ ホスホイノシチド３−キナーゼβの阻害
PL377354A1 (pl) * 2002-12-27 2006-01-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4H-pirydo[1,2-a]pirymidyny i związki pokrewne użyteczne jako inhibitory integrazy HIV
EP1454909B1 (en) 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
EP1460076A1 (en) 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1557417B1 (en) 2003-12-19 2007-03-07 Sanofi-Aventis Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
AR054438A1 (es) 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
JP2008542253A (ja) * 2005-05-26 2008-11-27 クドス ファーマシューティカルズ リミテッド Ｄｎａ損傷癌療法に対してａｔｍ欠損癌を感作するためのｄｎａ−ｐｋ阻害の使用
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
WO2008148074A2 (en) * 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same

Also Published As

Publication number Publication date
TWI455940B (zh) 2014-10-11
ES2487623T3 (es) 2014-08-22
PT2448940E (pt) 2014-09-03
MX2012000103A (es) 2012-05-22
SG10201403149YA (en) 2014-08-28
PL2448940T3 (pl) 2014-10-31
DK2448940T3 (da) 2014-08-25
AU2010267815B2 (en) 2015-07-16
RU2561130C2 (ru) 2015-08-20
CN102482286B (zh) 2015-07-15
WO2011001113A3 (fr) 2011-02-24
CA2766909C (fr) 2018-06-05
JP5655070B2 (ja) 2015-01-14
KR20120103553A (ko) 2012-09-19
AR077363A1 (es) 2011-08-24
US20120208810A1 (en) 2012-08-16
IL217293A (en) 2016-12-29
EP2448940B1 (fr) 2014-05-21
AU2010267815A1 (en) 2012-02-16
SG177464A1 (en) 2012-02-28
IL217293A0 (en) 2012-02-29
TW201105673A (en) 2011-02-16
WO2011001113A2 (fr) 2011-01-06
HRP20140786T1 (hr) 2014-11-07
CA2766909A1 (fr) 2011-01-06
HK1169388A1 (en) 2013-01-25
BRPI1015943A8 (pt) 2018-01-09
US8846670B2 (en) 2014-09-30
JP2012531463A (ja) 2012-12-10
CN102482286A (zh) 2012-05-30
EP2448940A2 (fr) 2012-05-09
SI2448940T1 (sl) 2014-10-30
MY155661A (en) 2015-11-13
RU2012103477A (ru) 2013-08-10
BRPI1015943A2 (pt) 2016-04-19

Similar Documents

Publication Publication Date Title
UY32754A (es) NUEVOS DERIVADOS DE 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA
UY30859A1 (es) Nuevos derivados de 2-anilino-4-heteroarilpirimidinas , su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
UY29549A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
UY29038A1 (es) Nuevos derivados de urea cíclicos sustituidos, su preparación y su uso farmacéutico como inhibidores de quinasa
UY30857A1 (es) Nuevos derivados de n,n'-2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
UY31651A1 (es) Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos.
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
UY29037A1 (es) Nuevos derivados de urea cíclicos sustituidos con heterociclo, su preparación y su uso farmacéutico como inhibidores de quinasa
UY30858A1 (es) Nuevos derivados de fenil-(4-fenil-pirimidin-2-il)- aminas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CU20130129A7 (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY35467A (es) Compuestos orgánicos
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
CO6781507A2 (es) Novedosos derivados heterociclicos
UY31997A (es) Nuevos derivados de imidazo[1,2-a]piridina, y sus nuevos usos como inhibidores de met.
ECSP11011391A (es) Métodos y productos intermedios para preparar agentes farmacéuticos
ECSP14013215A (es) Compuestos novedosos
UY31998A (es) Nuevos derivados de imidazo[1,2-a]pirimidina, y sus nuevos usos como inhibidores de met
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY34018A (es) Derivados glucósidos y usos de los mismos
UY31278A1 (es) Nuevos derivados de n, n??-2,4-dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
UY32755A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190211